Mark T. Iwicki

CIK: 0001415537

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (11.8%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)15 (44.1%)

Compensation grants

Other (G, F, J, C, D, …)15 (44.1%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (6)

QTTB

Q32 Bio Inc.

Director

IKT

Inhibikase Therapeutics, Inc.

DirectorOfficer

MRUS

Merus N.V.

Director

AKRO

Akero Therapeutics, Inc.

Director

KALA

KALA BIO, Inc.

DirectorOfficer

THRD

Third Harmonic Bio, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (34 total)

QTTB
Q32 Bio Inc.
Jun 12, 2026
Award(A)
Stock Option (Right to Buy)
Direct
10.8K shares-
QTTB
Q32 Bio Inc.
Jun 12, 2026
Award(A)
Stock Option (Right to Buy)
Direct
9.8K shares-
IKT
Inhibikase Therapeutics, Inc.
Jan 5, 2026
Award(A)
Stock Option (Right to Buy)
Direct
5M shares-
MRUS
Merus N.V.
Dec 12, 2025
Disposition(D)
Share Option (right to buy)
Direct
5K shares-
MRUS
Merus N.V.
Dec 12, 2025
Disposition(D)
Share Option (right to buy)
Direct
5.7K shares-
MRUS
Merus N.V.
Dec 12, 2025
Disposition(D)
Share Option (right to buy)
Direct
8.6K shares-
MRUS
Merus N.V.
Dec 12, 2025
Disposition(D)
Share Option (right to buy)
Direct
6.1K shares-
MRUS
Merus N.V.
Dec 12, 2025
Disposition(D)
Share Option (right to buy)
Direct
8.8K shares-
MRUS
Merus N.V.
Dec 12, 2025
Tender Offer(U)
Direct
73.6K shares at avg. $97.00$7.1M
MRUS
Merus N.V.
Dec 12, 2025
Disposition(D)
Share Option (right to buy)
Direct
8.5K shares-
MRUS
Merus N.V.
Dec 12, 2025
Disposition(D)
Share Option (right to buy)
Direct
14.4K shares-
MRUS
Merus N.V.
Dec 12, 2025
Disposition(D)
Share Option (right to buy)
Direct
13.2K shares-
MRUS
Merus N.V.
Dec 12, 2025
Disposition(D)
Share Option (right to buy)
Direct
16.6K shares-
AKRO
Akero Therapeutics, Inc.
Dec 9, 2025
Disposition(D)
Direct
9.4K shares-
QTTB
Q32 Bio Inc.
Oct 23, 2025
Award(A)
Stock Option (Right to Buy)
Direct
53.5K shares-
KALA
KALA BIO, Inc.
Oct 23, 2025
Sale(S)
Direct
154.9K shares at avg. $0.81$125K
THRD
Third Harmonic Bio, Inc.
Aug 11, 2025
Other(J)
Direct
128.6K shares-
KALA
KALA BIO, Inc.
Jun 24, 2025
Sale(S)
Direct
13.2K shares at avg. $4.01$53K
KALA
KALA BIO, Inc.
Jun 15, 2025
Award(A)
Direct
2.5K shares-
KALA
KALA BIO, Inc.
Jun 3, 2025
Sale(S)
Direct
10.9K shares at avg. $3.74$41K
AKRO
Akero Therapeutics, Inc.
Jun 3, 2025
Award(A)
Direct
9.4K shares-
MRUS
Merus N.V.
May 22, 2025
Award(A)
Share Option (right to buy)
Direct
13.2K shares-
QTTB
Q32 Bio Inc.
Feb 24, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
37.2K shares-
QTTB
Q32 Bio Inc.
Feb 24, 2025
Award(A)
Stock Option (Right to Buy)
Direct
25.5K shares-
QTTB
Q32 Bio Inc.
Feb 24, 2025
Disposition(D)
Stock Option (Right to Buy)
Direct
25.5K shares-

		Type	Shares	Price		Ownership
Jun 12, 2026	QTTB Q32 Bio Inc.	Award(A) Stock Option (Right to Buy)	10,826	-	-	Direct
Jun 12, 2026	QTTB Q32 Bio Inc.	Award(A) Stock Option (Right to Buy)	9,810	-	-	Direct
Jan 5, 2026	IKT Inhibikase Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	4,982,706	-	-	Direct
Dec 12, 2025	MRUS Merus N.V.	Disposition(D) Share Option (right to buy)	4,983	-	-	Direct
Dec 12, 2025	MRUS Merus N.V.	Disposition(D) Share Option (right to buy)	5,650	-	-	Direct
Dec 12, 2025	MRUS Merus N.V.	Disposition(D) Share Option (right to buy)	8,631	-	-	Direct
Dec 12, 2025	MRUS Merus N.V.	Disposition(D) Share Option (right to buy)	6,120	-	-	Direct
Dec 12, 2025	MRUS Merus N.V.	Disposition(D) Share Option (right to buy)	8,844	-	-	Direct
Dec 12, 2025	MRUS Merus N.V.	Tender Offer(U)	73,576	$97.00	$7,136,872	Direct
Dec 12, 2025	MRUS Merus N.V.	Disposition(D) Share Option (right to buy)	8,500	-	-	Direct
Dec 12, 2025	MRUS Merus N.V.	Disposition(D) Share Option (right to buy)	14,414	-	-	Direct
Dec 12, 2025	MRUS Merus N.V.	Disposition(D) Share Option (right to buy)	13,193	-	-	Direct
Dec 12, 2025	MRUS Merus N.V.	Disposition(D) Share Option (right to buy)	16,604	-	-	Direct
Dec 9, 2025	AKRO Akero Therapeutics, Inc.	Disposition(D)	9,398	-	-	Direct
Oct 23, 2025	QTTB Q32 Bio Inc.	Award(A) Stock Option (Right to Buy)	53,521	-	-	Direct
Oct 23, 2025	KALA KALA BIO, Inc.	Sale(S)	154,894	$0.81	$125,464	Direct
Aug 11, 2025	THRD Third Harmonic Bio, Inc.	Other(J)	128,631	-	-	Direct
Jun 24, 2025	KALA KALA BIO, Inc.	Sale(S)	13,227	$4.01	$53,040	Direct
Jun 15, 2025	KALA KALA BIO, Inc.	Award(A)	2,450	-	-	Direct
Jun 3, 2025	KALA KALA BIO, Inc.	Sale(S)	10,866	$3.74	$40,639	Direct
Jun 3, 2025	AKRO Akero Therapeutics, Inc.	Award(A)	9,398	-	-	Direct
May 22, 2025	MRUS Merus N.V.	Award(A) Share Option (right to buy)	13,193	-	-	Direct
Feb 24, 2025	QTTB Q32 Bio Inc.	Disposition(D) Stock Option (Right to Buy)	37,222	-	-	Direct
Feb 24, 2025	QTTB Q32 Bio Inc.	Award(A) Stock Option (Right to Buy)	25,534	-	-	Direct
Feb 24, 2025	QTTB Q32 Bio Inc.	Disposition(D) Stock Option (Right to Buy)	25,534	-	-	Direct

1-25 of 34 transactions

About Iwicki Mark T

Iwicki Mark T (SEC CIK 0001415537) files insider reports with the SEC as Director of Q32 Bio Inc. (QTTB), Chief Executive Officer of Inhibikase Therapeutics, Inc. (IKT) and Director of Merus N.V. (MRUS). Signal8 also holds filings tied to 3 other companies.

Signal8 holds 20 ownership filings by Iwicki Mark T (1 Form 3, 19 Form 4), filed between Jan 7, 2025 and Jul 21, 2026. Those filings report 34 transactions, from Jan 6, 2025 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Iwicki Mark T's filings is in WALTHAM, MA.

Recent filings by Iwicki Mark T

Jun 12, 2026: Grants or awards of QTTB derivative securities (2 lines, Form 4, code A).
Jan 5, 2026: Grant or award of IKT derivative securities (Form 4, code A).
Dec 12, 2025: Disposition to issuer transactions of MRUS derivative securities (5 lines, Form 4, code D).
Dec 12, 2025: Tender of shares transaction of MRUS shares (Form 4, code U).
Dec 12, 2025: Disposition to issuer transactions of MRUS derivative securities (4 lines, Form 4, code D).

Other insiders filing for Q32 Bio Inc. (QTTB)

Morrison Jodie Pope, CEO
Violette Shelia M., Chief Scientific Officer
Kalowski Lee, CFO and President
TZIANABOS ARTHUR, Director
Lundberg Sven Ante, Director
LAPORTE KATHLEEN, Director

How to read Form 4 transaction codes